SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-054448
Filing Date
2024-05-07
Accepted
2024-05-07 16:01:43
Documents
61
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q nmra-20240331.htm   iXBRL 10-Q 2066696
2 EX-10.1 nmra-ex10_1.htm EX-10.1 39575
3 EX-10.2 nmra-ex10_2.htm EX-10.2 58899
4 EX-31.1 nmra-ex31_1.htm EX-31.1 16416
5 EX-31.2 nmra-ex31_2.htm EX-31.2 16409
6 EX-32.1 nmra-ex32_1.htm EX-32.1 9715
7 EX-32.2 nmra-ex32_2.htm EX-32.2 9675
8 GRAPHIC img235846496_0.jpg GRAPHIC 759568
  Complete submission text file 0000950170-24-054448.txt   9794175

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT nmra-20240331.xsd EX-101.SCH 1254057
65 EXTRACTED XBRL INSTANCE DOCUMENT nmra-20240331_htm.xml XML 1276028
Mailing Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472 (857) 760-0900
Neumora Therapeutics, Inc. (Filer) CIK: 0001885522 (see all company filings)

IRS No.: 844367680 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41802 | Film No.: 24921653
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)